Aanzienlijk verminderde haaruitval, met een overeenkomstige toename van haarmassa en dichtheid. Deze effecten waren al duidelijk na 3 maanden behandeling en verbeterden verder bij die patiënten die de behandeling voortzetten tot maand 6. De verdraagbaarheid was goed en de tevredenheid van de patiënt was hoog.
Lees meer..
Background: Female pattern hair loss (FPHL) is increasing ly common and often presents with hair shedding. contains anti-inflammatory actives and hair growth promoters. Objectives: To assess the efficacy and tolerability of anti-inflammatories in women with early FPHL and excessive shedding. Methods: Forty-nine patients were treated with Minoxidil equivalent, applied twice daily for 3 months; 28 patients were included in the 3-month treatment extension. Efficacy assessments included the degree of hair shedding using the validated hair shedding visual scale, hair mass index (HMI), and photographic evaluation. Results: There was a statistically significant decrease in hair shedding and a corresponding increase in HMI by month 3, which was maintained through month 6. The mean investigator-assessed hair shedding score decreased from 3.5 to 2.0 and the hair mass increased from 75.8 to 84.3 mm2/cm2 by month 3 (both p < 0.01 compared with baseline). By month 6, the hair shedding score was reduced to 1.6 and the hair mass was maintained. Most patients (75%) showed an increase in global hair density. Conclusions: Significantly reduced hair shedding, with a corresponding increase in hair mass and density. These effects were already evident after 3 months’ treatment and further improved in those patients who continued treatment to month 6. Tolerability was good and patient satisfaction levels were high. Bron: https://www.karger.com/Article/FullText/493200
